[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602014":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":25,"locations":34,"responsibleParty":48,"collaborators":25,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":25,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":73,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Radicle Science","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Control 1","PLACEBO_COMPARATOR","Radicle Revive Placebo Control Form 1",[13],"Dietary Supplement: Radicle Revive Placebo Control Form 1",{"label":15,"type":16,"description":17,"interventionNames":18},"Active Product 1","EXPERIMENTAL","Radicle Revive Active Study Product 1",[19],"Dietary Supplement: Radicle Revive Active Study Product 1",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.",[9],null,{"type":22,"name":17,"description":27,"armGroupLabels":28,"otherNames":25},"Participants will use their Radicle Revive Active Study Product 1 as directed for a period of 6 weeks.",[15],[30],{"name":31,"affiliation":32,"role":33},"Susan Hewlings","Radicle Science Inc.","PRINCIPAL_INVESTIGATOR",[35],{"facility":36,"status":25,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"Radicle Science, Inc","Del Mar","California","92014-2605","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.26531,32.95949,{"lat":46,"lon":45},{"type":49,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100602014","radicle-revive-24-a-study-of-health-and-wellness-products-on-hormonal-health-and-associated-health-outcomes-in-women-with-peri-menopausal-health-issues-100602014",false,"NCT07117994","Radicle Revive 24: A Study of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women With Peri-Menopausal Health Issues","Radicle Revive™ 24_VPH: A Randomized, Double-Blind, Placebo-Controlled, Direct-to-Consumer Trial Assessing the Impact of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women With Peri-Menopausal Health Issues","Inclusion Criteria:\n\n* Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n* Assigned sex at birth is female\n* Resides in the United States\n* Identifies menstrual status as perimenopausal\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Indicates having peri-menopausal issues for 3 months or longer\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\nExclusion Criteria:\n\n* Individuals who report any of the following during screening will be excluded from participation:\n* Reports being pregnant or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n* NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n* Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk to participants\n* Reports an allergy to and\u002For disinterest in any of the possible study product ingredients\n* Lack of reliable daily access to the internet",true,"FEMALE","40 Years","105 Years",{"count":62,"type":63},500,"ACTUAL","INTERVENTIONAL",[66],"NA","A Randomized, Double-Blind, Placebo-Controlled, Direct-to-Consumer Trial Assessing the Impact of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women with Peri-Menopausal Health Issues",[69,70,71,72],"Stress","Menopause","Fatigue","Sleep","COMPLETED","2025-12-09",{"date":76,"type":63},"2025-12-17",{"date":78,"type":63},"2025-08-05",{"date":80,"type":63},"2025-11-12",{"name":5,"class":6},1]